Search for Clinical Trial Results
Ependymoma - 154 Studies Found
Status | Study |
Terminated |
Study Name: Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma Condition:
Date: 2007-01-30 Interventions: |
Terminated |
Study Name: Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Condition:
Date: 2005-05-03 Interventions: |
Completed |
Study Name: Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Condition:
Date: 2002-02-14 Interventions: |
Terminated |
Study Name: Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases Condition:
|
Withdrawn |
Study Name: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Condition:
|
Terminated |
Study Name: Antineoplaston Therapy in Treating Patients With Ependymoma Condition: Ependymoma Date: 1999-11-01 Interventions: Drug: Antineoplaston therapy (Atengenal + Astugenal) Patients with an ependymoma will receive Antineopla |
Terminated |
Study Name: Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma Condition: Ependymoma Date: 2010-03-16 Interventions: Drug: Carboplatin Patients will receive daily carboplatin as a radiation sensitizer prior to radiation e |
Recruiting |
Study Name: Everolimus for Children With Recurrent or Progressive Ependymoma Condition: Recurrent Childhood Ependymoma Date: 2014-05-29 Interventions: Drug: Everolimus The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, unt |
Recruiting |
Study Name: A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma Condition: Ependymoma Date: 2014-04-25 Interventions:
|
Recruiting |
Study Name: Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod Condition: Ependymoma Date: 2013-02-12 Interventions:
|